OBJECTIVE: Complement activation has been suggested to play a role in atherogenesis. To study the regulation of complement activation in human coronary atherosclerotic lesions, we examined the spatial relationships between the major complement inhibitor, factor H, and the complement activation products C3d and C5b-9. METHODS AND RESULTS: In early lesions (American Heart Association types II and III), factor H was immunohistochemically found in the superficial proteoglycan-rich layer in association with numerous macrophages and C3d, whereas C5b-9 was found deeper in the intima, where factor H was virtually absent. In vitro experiments involving surface plasmon resonance and affinity chromatography analyses demonstrated that isolated human arterial proteoglycans bind factor H, and functional complement assays showed that glycosaminoglycans inhibit the complement activation induced by modified low density lipoprotein or by a foreign surface. CONCLUSIONS: The present observations raise the possibility that proteoglycans, because of their ability to bind the major complement inhibitor factor H, may inhibit complement activation in the superficial layer of the arterial intima. In contrast, deeper in the intima, where factor H and proteoglycans are absent, complement may be activated and proceed to C5b-9. Thus, the superficial and the deep layers of the human coronary artery appear to differ in their ability to regulate complement activation.
OBJECTIVE: Complement activation has been suggested to play a role in atherogenesis. To study the regulation of complement activation in humancoronary atherosclerotic lesions, we examined the spatial relationships between the major complement inhibitor, factor H, and the complement activation products C3d and C5b-9. METHODS AND RESULTS: In early lesions (American Heart Association types II and III), factor H was immunohistochemically found in the superficial proteoglycan-rich layer in association with numerous macrophages and C3d, whereas C5b-9 was found deeper in the intima, where factor H was virtually absent. In vitro experiments involving surface plasmon resonance and affinity chromatography analyses demonstrated that isolated human arterial proteoglycans bind factor H, and functional complement assays showed that glycosaminoglycans inhibit the complement activation induced by modified low density lipoprotein or by a foreign surface. CONCLUSIONS: The present observations raise the possibility that proteoglycans, because of their ability to bind the major complement inhibitor factor H, may inhibit complement activation in the superficial layer of the arterial intima. In contrast, deeper in the intima, where factor H and proteoglycans are absent, complement may be activated and proceed to C5b-9. Thus, the superficial and the deep layers of the human coronary artery appear to differ in their ability to regulate complement activation.
Authors: Riikka Tulamo; Juhana Frösen; Anders Paetau; Sanna Seitsonen; Juha Hernesniemi; Mika Niemelä; Irma Järvelä; Seppo Meri Journal: Am J Pathol Date: 2010-10-22 Impact factor: 4.307
Authors: N Bahia El Idrissi; S Hakobyan; V Ramaglia; A Geluk; B Paul Morgan; P Kumar Das; F Baas Journal: Clin Exp Immunol Date: 2016-03-31 Impact factor: 4.330
Authors: Vinay K Bhatia; Sheng Yun; Viola Leung; David C Grimsditch; G Martin Benson; Marina B Botto; Joseph J Boyle; Dorian O Haskard Journal: Am J Pathol Date: 2007-01 Impact factor: 4.307
Authors: J Jylhävä; C Eklund; T Pessi; O T Raitakari; M Juonala; M Kähönen; J S A Viikari; T Lehtimäki; M Hurme Journal: Clin Exp Immunol Date: 2009-01 Impact factor: 4.330
Authors: Ian A Thompson; Baoying Liu; H Nida Sen; Xiadong Jiao; Robert Katamay; Zhiyu Li; Mengjun Hu; Fielding Hejtmancik; Robert B Nussenblatt Journal: Am J Ophthalmol Date: 2013-03-14 Impact factor: 5.258